Lavipharm S.A (LAVI) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Lavipharm S.A stock €0.52, price €1.49, that is 65.1% below the price, quality 52 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range €0.3341 – €2.00 · fair‑value band €0.2800 – €0.8000 · the €1.49 price screens above the €0.5200 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Lavipharm in your weekly email
Every Wednesday you see whether Lavipharm is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Lavipharm S.A. engages in the research, development, manufacturing, import, marketing, sale, and wholesaling of pharmaceutical, dermocosmetic, and healthcare products in Greece and internationally.
Show moreShow less
The company offers pharmaceutical products for cardiology, chronic pain and oncology, central nervous system, respiratory system, gastrointestinal system, and urology; and over the counter (OTC) drugs, such as antiseptics, anagelsics, and anti-lice treatment products.
It also provides a range of skincare products focused on health. The company was founded in 1911 and is based in Paiania, Greece.
Stock analysis
Lavipharm S.A (LAVI) currently trades at €1.49, while our model-based Fair Value estimate is €0.5200, 65% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of €0.6850 per share, and 0 of the 26 models we run sit above the €1.49 price.
Bear case: the Dividend Discount group reads lowest at €0.1700, and 26 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: €0.2800 (bear) to €0.8000 (bull), the price of €1.49 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Lavipharm S.A reported revenue of €62.6M in FY2025 versus €39.7M in FY2021, a compound +12.0%/yr. Reported net income was €6.0M in FY2025, compounding +36.5%/yr from FY2021.
Key figures
Market cap €258M Micro · P/E ratio 49.6 · P/S ratio 4.10 · EPS (TTM) €0.0300 · Dividend yield 1.3% · Net margin 8.2% · Return on equity 10.2% · Return on assets (EBIT) 5.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (low confidence).
What moves the price
The share trades about 13% below its 52-week high and 83% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −65%, LAVI screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (€0.0300 to €1.08). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear€0.2800Fair Value €0.5200Bull€0.8000
Price €1.49 · Downside -65.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€0.0086 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.68/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+18.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.7%
Start year 2020 (pandemic). Over 10 years: +9.0% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
−19.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−20.4%
Dividend (yield on the price)1.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−21.4% vs −15.9%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 14%
2025 sits 218% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 21.7%/yr over ~7Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+64.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +61.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 551 stocks
Beats the industry median on 5/14 measures
Overall it trails its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside−65.1% · Bottom 25%
Profitability
Return on equity (12 months)10.2% · Above median
Return on assets4.6% · Above median
Net margin (12 months)8.2% · Above median
Operating margin (12 months)13.6% · Above median
Growth and dividend
Revenue growth (quarter YoY)41.3% · Top 25%
Dividend yield (12 months)1.3% · Below median
Balance sheet
Debt / equity0.18× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Lavipharm S.A Fair Value". https://www.fairvalue-calculator.com/stock/LAVI
Frequently asked questions
Is Lavipharm S.A (LAVI) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of €0.5200 versus a price of €1.49, about 65% lower (overvalued).
What is the fair value of LAVI?
Our model-based fair value for Lavipharm S.A is €0.5200 (as of Nov 6, 2026), built from audited fundamentals. The current price: €1.49.
What is the quality score of LAVI?
Lavipharm S.A has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lavipharm S.A (LAVI)?
Our model-based price target is the fair value of €0.5200 (as of Nov 6, 2026) from 26 valuation models. Cautious scenario €0.2800, optimistic scenario €0.8000. It is a calculation from audited fundamentals, not an analyst target.
What is the Lavipharm S.A stock forecast for 2026?
Our models put fair value at €0.5200, about 65% lower versus a price of €1.49 (overvalued). Cautious scenario €0.2800, optimistic scenario €0.8000. The calculation is refreshed regularly with new filings.
What is the revenue of Lavipharm S.A (LAVI)?
Lavipharm S.A reported trailing-twelve-month revenue of about €70.3M (latest available figure, as of Nov 6, 2026).
Does Lavipharm S.A pay a dividend?
Lavipharm S.A currently shows a dividend yield of 1.34% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Lavipharm S.A (LAVI) and when is the ex-dividend date?
Lavipharm S.A pays a dividend of €0.02 per share a year, a dividend yield of 1.3%. The last ex-dividend date was Jul 20, 2026. The payout ratio is 66.7% of earnings. Free cash flow covers the dividend 0.60 times. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What growth is priced into Lavipharm S.A (LAVI)?
For today's price to be fair in a discounted-cash-flow model, Lavipharm S.A would have to grow free cash flow by +64.8 % per year for five years (discount rate 15.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +10.7 % per year. Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of LAVI use?
Our models discount Lavipharm S.A at 15.4 %: a base by market capitalisation (micro), damped by beta 1.01, country premium for Greece. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Lavipharm S.A that is +64.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (15.4 %) and the same formula as our fair value.
How much growth has Lavipharm S.A (LAVI) delivered so far?
Over the past 5 years revenue at Lavipharm S.A grew +10.7 % a year. The price currently implies free-cash-flow growth of +64.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Lavipharm S.A (LAVI) growing?
The median revenue growth in the sector is +6.3 % a year. That is the yardstick for the growth priced into Lavipharm S.A (+64.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Lavipharm S.A (LAVI)?
The free-cash-flow yield on the price is 0.79 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow Lavipharm S.A produces per unit of market value. When it exceeds the discount rate of our models (15.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Lavipharm S.A (LAVI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lavipharm S.A it is €0.5200 per share (as of Nov 6, 2026), against a price of €1.49. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Lavipharm S.A stock overvalued or undervalued in 2026?
As of Nov 6, 2026, LAVI trades above its calculated fair value: price €1.49, fair value €0.5200, a gap of about −65% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LAVI?
No. The price is what the market pays today (€1.49); the fair value is what the company's own numbers justify (€0.5200). For Lavipharm S.A the two are €0.9680 per share apart. That gap is exactly why we show both numbers side by side.
How much is Lavipharm S.A worth?
The market values Lavipharm S.A at about €258M (market capitalisation, as of Nov 6, 2026). Per share that is €1.49; our models calculate a fair value of €0.5200 per share.
What do the bullish and bearish scenarios say about LAVI?
Our models span a range for Lavipharm S.A: cautious scenario €0.2800, base €0.5200, optimistic €0.8000 per share (as of Nov 6, 2026, price €1.49). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of LAVI?
Lavipharm S.A trades at a price-to-earnings ratio of 49.6 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €0.5200 is built from several models across several years. Other multiples: P/B 5.1, P/S 4.1, EV/EBITDA 21.8.
How solid is the balance sheet of Lavipharm S.A (LAVI)?
Balance-sheet figures for Lavipharm S.A (as of Nov 6, 2026): return on equity 10.2%, debt of 0.18 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is LAVI from its 52-week high?
Lavipharm S.A trades at €1.49, about 13% below its 52-week high of €1.70 and 83% above the low of €0.8130 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of €0.5200 is for.
Which stocks are comparable to Lavipharm S.A?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lavipharm S.A stock attractive at the current price?
The data as of Nov 6, 2026: price €1.49, calculated fair value €0.5200 (−65%), Quality Score 52/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LAVI calculated?
We run Lavipharm S.A through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of €0.5200 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Lavipharm S.A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lavipharm S.A (LAVI)?
The closing price on Nov 9, 2026 was €1.49. Our model-based fair value is €0.5200, about 65% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lavipharm S.A right now?
The price sits above even our optimistic bull case (€0.8000). The favourable scenario is already priced in. The model range is unusually wide (€0.2800 to €0.8000). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Lavipharm S.A
How large is the market capitalisation of Lavipharm S.A (LAVI)?
The market capitalisation of Lavipharm S.A is €258M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Lavipharm S.A (LAVI)?
The price-to-sales ratio of Lavipharm S.A is 4.10 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Lavipharm S.A (LAVI)?
Earnings per share at Lavipharm S.A are €0.0300 (price ÷ EPS = P/E 49.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Lavipharm S.A (LAVI)?
The dividend yield of Lavipharm S.A is 1.3% (payout 66.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Lavipharm S.A (LAVI)?
The net margin of Lavipharm S.A is 8.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Lavipharm S.A (LAVI)?
The return on equity (ROE) of Lavipharm S.A is 10.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lavipharm S.A (LAVI)?
On an EBIT basis the return on assets of Lavipharm S.A is 5.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lavipharm S.A (LAVI)?
The operating margin of Lavipharm S.A is 13.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Lavipharm S.A (LAVI)?
Revenue at Lavipharm S.A is growing +41.3% versus a year earlier (3y avg +10.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Lavipharm S.A (LAVI)?
Earnings per share at Lavipharm S.A are growing +54.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Lavipharm S.A (LAVI) carry?
The net debt of Lavipharm S.A is €14.5M (fiscal year 2025, ≈ 7.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Lavipharm S.A in the live analysis
One click puts Lavipharm S.A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 6, 2026